Skip to main content

“The pandemic year of 2020 was exceptional and very challenging for Sartorius as well. In a very intense and demanding environment, we experienced the strongest year of growth in the company's recent history and were simultaneously able to complete several strategically important acquisitions. Our strategy and business model proved not only to be particularly resilient in the face of the pandemic. Sartorius has also been contributing directly toward overcoming this pandemic: each and every day, we deliver essential products and technologies to vaccine manufacturers all over the world for producing coronavirus vaccines.”

Chairman’s Message

Sales revenue


in constant FX: 30.2%

Underlying EBITDA



Order intake


in constant FX: 49.0%




Market capitalization



Group Business Development and Divisions

Sartorius recorded high growth in 2020 due to strong organic development, several acquisitions and the additional momentum from business related to the coronavirus pandemic. The Group closed the year with significant double-digit growth rates in sales revenue, order intake and earnings, reporting further gains in both divisions and across all geographies.

Group Business Development

Bioprocess Solutions

In the Bioprocess Solutions Division, Sartorius offers a broad product portfolio that covers all steps in the production of a biopharmaceutical. The company has held leading market positions for years in its core technologies, such as filtration, fermentation, cell cultivation and fluid management.

Business Development of Bioprocess Solutions

Lab Products & Services

The Lab Products & Services Division offers laboratories in the pharmaceutical and biopharmaceutical industries as well as at academic research institutes innovative solutions for bioanalytics, in addition to premium laboratory products, consumables and services. Sartorius is among the market leaders in laboratory balances, pipettes and lab consumables.

Business Development of Lab Products & Services


Sartorius expects strong growth for 2021 and beyond. Therefore, with the publication of the 2021 forecast, the company has also considerably raised its mid-term targets for 2025.



Sartorius plans to grow profitably in 2021 as well. Consolidated sales revenue is thus projected to increase by about 19% to 25%. Regarding profitability, the company forecasts that its underlying EBITDA margin will be about 30.5%, up from 29.6% a year earlier.



Strategy and Long-Term Targets

In view of the strong results in 2020 and the forecasts regarding future organic growth potential, Sartorius has raised its mid-term targets. Consolidated sales revenue is expected to rise to about 5 billion euros by 2025 (previous target: around 4 billion euros) and the underlying EBITDA margin to around 32% (former guidance: around 28%).